Keheala

Saving Lives By Delivering Powerful Behavioral Interventions Across Mobile Phones

We deliver powerful behavioral interventions and disease management tools across mobile phones to improve healthcare access and treatment outcomes.

We recognized that community stigmas, poor information and a lack of support often thwart effective medical treatment.

The Social and Non-Medical Drivers of Disease

We're on a mission to change that.

Our Solution

Disease Management Tools reduce the patient burden

Behavioral Interventions from the social sciences maximize adherence and motivation

Non-Stigmatizing Support

Data and Analytics focus limited resources

Accessible by mobile phone without download

In 2016, we launched Keheala in Kenya to combat Tuberculosis (TB). The test case included 1,200 patients from 17 clinical sites.

LEARN MORE

Patients using Keheala achieved a 96% treatment success rate.

See More Of Our Impact

In the near future, we will expand our disease offerings and deliver new products that address some of the greatest public health challenges with our behavioral insights.

We are passionate about community and collaboration.

We all play a part. Join us on our journey.

Get Involved

Awards & Recognition

Global Health Innovation Index

USAID's Global Health Innovation Index Recognizes Keheala. The publication highlights Keheala as one of nine innovators with demonstrated impact and readiness for scale

Top Medical Journal, The New England Journal of Medicine, Published Keheala’s Innovative Work

The New England Journal of Medicine, one of the most prestigious medical journals in the world, published results from Keheala’s 1,200 tuberculosis-patient randomized control trial in Nairobi, Kenya. The publication highlights a 68% reduction in the unsuccessful health outcomes amongst Keheala patients.

Top Operations Research Journal, MSOM, Publishes Keheala Machine Learning Work

Keheala Powers Feature Phones with Machine Learning Algorithms to Improve TB Care in Africa. Collaboration with researchers from MIT and the University of Wisconsin results in publication of “Improving Tuberculosis Treatment Adherence Support: The Case for Targeted Behavioral Interventions” in the industry-leading journal.

Sanofi VivaTech AfricaTech Challenge

Sanofi, the fifth largest pharmaceutical company in the world, selected Keheala to compete in the AfricaTech Challenge at VivaTech 2019. Of 220 startups considered, Keheala took second place in its group.

World Summit Awards Country Nomination

Keheala selected as best national digital solution for international World Summit Awards.

TechEmerge Brazil, a World Bank Initiative

TechEmerge, a World Bank Group initiative, selected Keheala from amongst 295 tech companies representing 34 countries to participate in the TechEmerge Health Brazil Summit. Keheala will be eligible to apply for up to US$1M in funding available to support implementation of local pilots of cutting-edge tech solutions that can increase access to affordable quality healthcare and ultimately improve patient outcomes.

MassChallenge Finalist

Keheala was selected from a pool of over 500 applicants to participate in MassChallenge Israel’s 2018 accelerator program.

Teva's Rise Challenge Digital Health Award

The RISE Challenge, a global “innovation competition aiming to find novel solutions to real patient needs worldwide” was launched in 2016 to identify the most innovative solutions in several categories of care (diagnostics, inhaler design, etc.). Keheala was selected as the winner of the ‘Digital Health’ category. This award recognizes Keheala’s “potential for significant impact on the health and wellness of millions of people throughout the world in terms of effectiveness and reach.” As a part of the award, Keheala has received a cash prize. This is the first award Keheala has received from a major pharmaceutical company.

2018 International Social and Behavior Change Communication Conference Oral Abstract Selection

Keheala was selected to give an oral presentation at the 2018 International Social and Behavior Change Communication Conference in Nusa Dua, Indonesia. Over 900 abstracts were considered for oral presentation.

IZI Awardee

Nefesh B’Nefesh awarded Keheala the Initiative for Zionist Innovation (IZI) award, which seeks “the next generation of leaders and innovators.” A cash prize was received by Keheala as part of this recognition.

World Lung Health Conference Oral Presentation

Keheala was selected from among 1,700 submissions to give an oral presentation of its study results at The 48th Union World Lung Health Conference in Guadalajara, Mexico. Additionally, Keheala presented at the Stop TB Partnership's 1st Focus Group Discussion on Adherence Technologies.

Participant of the 8200 Social Program

Keheala was selected from among 176 companies to participate in the third cycle of the elite 8200 Social Program - an exclusive technology and business accelerator.